



Caffeine has a dual influence on NMDA receptor-mediated glutamatergic transmission at the hippocampus

Robertta S. Martins^{1,2} · Diogo M. Rombo^{1,3} · Joana Gonçalves-Ribeiro^{1,3} · Carlos Meneses⁴ · Vladimir P. P. Borges-Martins² · Joaquim A. Ribeiro^{1,3} · Sandra H. Vaz^{1,3} · Regina C. C. Kubrusly² · Ana M. Sebastião^{1,3}

Received: 19 June 2020 / Accepted: 20 August 2020

© Springer Nature B.V. 2020

Abstract

Caffeine, a stimulant largely consumed around the world, is a non-selective adenosine receptor antagonist, and therefore caffeine actions at synapses usually, but not always, mirror those of adenosine. Importantly, different adenosine receptors with opposing regulatory actions co-exist at synapses. Through both inhibitory and excitatory high-affinity receptors (A_1R and $A_{2A}R$, respectively), adenosine affects NMDA receptor (NMDAR) function at the hippocampus, but surprisingly, there is a lack of knowledge on the effects of caffeine upon this ionotropic glutamatergic receptor deeply involved in both positive (plasticity) and negative (excitotoxicity) synaptic actions. We thus aimed to elucidate the effects of caffeine upon NMDAR-mediated excitatory post-synaptic currents (NMDAR-EPSCs), and its implications upon neuronal Ca^{2+} homeostasis. We found that caffeine (30–200 μM) facilitates NMDAR-EPSCs on pyramidal CA1 neurons from Balbc/ByJ male mice, an action mimicked, as well as occluded, by 1,3-dipropyl-cyclopentylxanthine (DPCPX, 50 nM), thus likely mediated by blockade of inhibitory A_1R s. This action of caffeine cannot be attributed to a pre-synaptic facilitation of transmission because caffeine even increased paired-pulse facilitation of NMDA-EPSCs, indicative of an inhibition of neurotransmitter release. Adenosine $A_{2A}R$ s are involved in this likely pre-synaptic action since the effect of caffeine was mimicked by the $A_{2A}R$ antagonist, SCH58261 (50 nM). Furthermore, caffeine increased the frequency of Ca^{2+} transients in neuronal cell culture, an action mimicked by the A_1R antagonist, DPCPX, and prevented by NMDAR blockade with AP5 (50 μM). Altogether, these results show for the first time an influence of caffeine on NMDA receptor activity at the hippocampus, with impact in neuronal Ca^{2+} homeostasis.

Keywords Caffeine · NMDAR · Hippocampus · A_1 adenosine receptor · A_{2A} adenosine receptor

Abbreviations

A_1R	Adenosine A_1 receptor	AD	Alzheimer's disease
$A_{2A}R$	Adenosine A_{2A} receptor	AMPA	α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
aCSF	Artificial cerebrospinal fluid	AP5	DL-2-Amino-5-phosphonopentanoic acid
		ARs	Adenosine receptors
		CA1	<i>Cornu Ammonis</i> 1
		Ca^{2+}	Calcium ion
		CNQX	6-Cyano-7-nitroquinoxaline-2,3-dione disodium salt hydrate
		CNS	Central nervous system
		DIC	Day in culture
		DIC-IR	Differential interference contrast-infrared
		DPCPX	8-Cyclopentyl-1,3-dipropylxanthine
		EDTA	Ethylenediaminetetraacetic acid
		EPSCs	Excitatory post-synaptic currents
		F340/380	Ratio from excitation wavelength 340 nm and 380 nm

✉ Ana M. Sebastião
anaseb@medicina.ulisboa.pt

¹ Instituto de Farmacologia e Neurociências, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal

² Laboratório de Neurofarmacologia, Departamento de Fisiologia e Farmacologia, Pós-Graduação em Neurociências, Universidade Federal Fluminense, Niterói, Brazil

³ Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal

⁴ Área Departamental de Engenharia de Electrónica e Telecomunicações e de Computadores, Instituto Superior de Engenharia de Lisboa, Lisbon, Portugal

FBS	Fetal bovine serum
fEPSP	Field excitatory post-synaptic potential
GABA	Gamma-aminobutyric acid
HBSS	Hank's balanced salt solution
LTD	Long-term depression
LTP	Long-term potentiation
mGluR	Metabotropic glutamate receptors
NMDA	N-Methyl-D-aspartate
NMDAR	N-Methyl-D-aspartate receptor
N M D A R -	N-Methyl-D-aspartate receptor
EPSCs	excitatory post-synaptic potential
PDL	Poly-D-lysine
PPF	Paired-pulse facilitation
S.E.M.	Standard error of the mean

Introduction

Caffeine is a psychoactive drug widely consumed in the world and has a plethora of actions in the central nervous system (CNS) [1]. Nowadays, in addition to traditional beverages such as coffee and tea, caffeine can be found in energy drinks, soft drinks, and chocolates [2, 3]. The consumption of these products increased in recent years, including in children and adolescents [4–6], and may even exceed the recommended daily intake (2.5 mg/kg for 6–12 years old children) due to advertisements designed to attract these young consumers [7–9].

Caffeine is a methylxanthine with several mechanisms of action, such as non-selective antagonism of adenosine receptors, as the high-affinity A_1 and A_{2A} adenosine receptor (A_1R and $A_{2A}R$) subtypes, inhibition of cyclic nucleotide phosphodiesterases, mobilization of Ca^{2+} from the sarcoplasmic reticulum or inhibition of its reuptake, inhibition of monoamine oxidase and cyclooxygenase enzymes, and blockade of $GABA_A$ receptors [2, 10–15].

Adenosine A_1R and $A_{2A}R$ are widely distributed in the CNS. The A_1R is expressed in pre- and post-synaptic sites [16, 17] with its greatest expression on the cortex, cerebellum, and hippocampus [16, 18, 19]. The $A_{2A}R$ is mostly expressed in the basal ganglia but it is also present in the cortex and hippocampus, with pre- and post-synaptic actions being reported [20–24].

Adenosine is a homeostatic regulator of neuronal function, and therefore the blockade of its receptors by caffeine impacts on central nervous system activity. This has been explored in the context of the putative therapeutic actions of caffeine. Indeed, since $A_{2A}R$ can promote excitotoxicity, several studies have looked for neuroprotective effects of caffeine or related compounds in neurodegenerative diseases, including memory impairment observed in Alzheimer's disease (AD) or aging [14, 25, 26]. In addition, several studies have identified an effect of caffeine on synaptic plasticity, learning, and memory, which is usually observed after long-term caffeine

treatment, and demonstrate an improvement in hippocampus-dependent learning, short-term memory, and LTP, in animal models for AD, sleep deprivation, or aging [27–29].

The A_1R antagonism is responsible for the excitatory effect of caffeine upon synaptic transmission, while $A_{2A}R$ antagonism mediates the inhibitory action of caffeine upon synaptic plasticity [28, 30]. N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor involved not only in several forms of synaptic plasticity but also in excitotoxicity due to its Ca^{2+} -permeable ion channel properties [31, 32]. Direct evidence for post-synaptic modulation of hippocampal NMDA receptors by adenosine A_1R has been obtained long ago [33, 34], while $A_{2A}R$ has been recently reported as post-synaptic modulators of NMDA receptors at the hippocampus of young adult rats [24]. $A_{2A}R$ is also known to interact with other neurotransmitter receptors to control NMDA receptor activity at the hippocampus [35–40].

The impact of adenosine A_1R - and $A_{2A}R$ -mediated NMDA receptor modulation for neuroprotection, synaptic plasticity, learning, and memory has been repeatedly highlighted and discussed [24, 35, 41–46]. Since caffeine antagonizes A_1R and $A_{2A}R$, and since these receptors co-exist at different levels at the tripartite synapses, frequently having opposite roles in neuronal function, it is of uttermost importance to understand how this widely consumed substance modulates a receptor that also has a dual role on synapses. Therefore, the aim of this work was to evaluate the acute effect of caffeine on NMDAR-mediated currents of pyramidal neurons of the hippocampal *Cornu Ammonis* 1 region (CA1), as well as to evaluate the contribution of this action of caffeine on Ca^{2+} signaling in hippocampal neurons.

Experimental procedures

All experimental procedures were performed according to European Community Guidelines (Directive 2010/63/EU) and the Portuguese Law (DL 113/2013) for animal care for research purposes and were approved by the “Instituto de Medicina Molecular João Lobo Antunes” Internal Committee and the Portuguese Animal Ethics Committee-Direcção Geral de Veterinária.

Whole cell patch clamp recordings

Young mice Balbc/ByJ males (PN35–48 days) were deeply anesthetized with isoflurane and euthanized by decapitation. The brain was quickly removed and hemispheres isolated for hippocampal dissection in 4 °C dissecting solution containing (in mM) sucrose 110; KCl 2.5; $CaCl_2$ 0.5; $MgCl_2$ 7; $NaHCO_3$ 25; NaH_2PO_4 1.25; and glucose 7, pH = 7.4, aired with 95% O_2 and 5% CO_2 . Transversal hippocampal slices (300 μ m thick) were made using a vibratome (Leica VT 1000S; Leica

Microsystems, Germany) routinely in the laboratory (e.g., [24]). Slices were then incubated for 30 min at 35 °C in artificial cerebrospinal fluid (aCSF) containing (mM) NaCl 124; KCl 3; NaH₂PO₄ 1.25; NaHCO₃ 26; MgSO₄ 1; CaCl₂ 2; and glucose 10, pH 7.4, gassed with 95% O₂ and 5% CO₂, and then allowed to further energetic recover at room temperature for at least 1 h, before starting recordings. Throughout the recording period, the aCSF was supplemented with 5 μM glycine and no Mg²⁺ was added.

For recordings, individual slices were fixed with a grid in a recording chamber and continuously superfused with modified aCSF (supplemented with 5 μM glycine and no Mg²⁺) at room temperature by a gravitational superfusion system at 2–3 mL/min. NMDAR-mediated synaptic currents were pharmacologically isolated with the addition of picrotoxin (GABA_A receptor blocker—50 μM) and 6-cyano-7-nitroquinoxaline-2,3-dione disodium salt hydrate (CNQX—α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) blocker—10 μM) to the perfusion medium (modified aCSF) during all recording time. Recorded signals were allowed to stabilize for at least 10 min before the addition of any test drug. Tested drugs were added to the superfusion solution; 0 min in the time-course figures indicate the time at which the changeover of solutions was initiated. When caffeine was tested in presence of other drug, caffeine was added to superfusion solution at 0 min, while the other drug was added at least for 10 min, before caffeine addition, during the baseline period, as indicated in the time-course figures. Whenever changing solutions, around 2–3 min elapsed before the new solution reaches the recording chamber.

Patch pipettes (4–9 MΩ) were pulled from borosilicate glass capillaries (1.5-mm outer diameter, 0.86 inner diameter, Harvard Apparatus) with a PC-10 Puller (Narishige Group) and filled with an intracellular solution containing (mM) K-gluconate 125; KCl 11; CaCl₂ 0.1; MgCl₂ 2; EGTA 1; HEPES 10; MgATP 2; NaGTP 0.3; and phosphocreatine 10, pH 7.3, adjusted with KOH (1 M), 280–290 mOsm. Electrode positioning and cell selection were performed under visual guidance using a Carl Zeiss Axioskop 2FS upright microscope (Jena, Germany) equipped with a differential interference contrast-infrared (DIC-IR) CCD video camera (VX44, Till Photonics, Gräfelfing, Germany).

Recordings from CA1 pyramidal cells were performed in voltage-clamp mode (V_h = −60 mV) with an Axopatch 200B amplifier (Axon Instruments, CA, USA). Excitatory post-synaptic currents (EPSCs) were electrically evoked every 15 s by an electric pulse delivered through a bipolar concentric electrode (Advent Research Materials) placed on the side fibers of Schaffer collaterals. For the paired-pulse facilitation (PPF) assessment, 2 pulses separated by 250 ms were delivered every 15 s. The junction potential was not compensated for and offset potentials were nulled before giga-seal formation. Small voltage steps (5 mV,

50 ms) were delivered throughout the experiment to monitor the access resistance; the holding current was also constantly monitored and when any of these parameters varied by more than 20%, the experiment was rejected. The current signal was low-pass filtered using a 3- and 10-kHz three-pole Bessel filter, digitized at 10 kHz using a Digidata 1322A board, and registered by the Clampex software version 10.2 (Molecular Devices, Sunnyvale, CA, USA). Data analysis was performed with Clampfit 10 (included in pCLAMP 10).

Primary culture of neurons

Primary purified neuron cultures were prepared according to established methodology (e.g., [47]). Briefly, Sprague-Dawley fetuses (pre-natal day 18/19) were sacrificed and their brains used to grow primary neuronal cultures. The fetuses were collected in Hank's balanced salt solution (HBSS), their cerebral cortex together with the hippocampus was isolated, the meninges were removed, and the tissue was prepared for co-culture. The obtained tissues were mechanically fragmented and digested with 10% (v/v) trypsin-ethylenediaminetetraacetic acid (EDTA) in HBSS for 15 min at 37 °C. Trypsin action was stopped with the addition of a solution with 30% (v/v) fetal bovine serum (FBS) in HBSS, followed by 3× centrifugation at 1200 rpm (Eppendorf, 5810R, Hamburg, Germany); in each cycle, the medium was discarded and renewed with 30% (v/v) FBS in HBSS solution. After the last centrifugation, cells were resuspended in supplemented Neurobasal medium (0.5 mM L-glutamine, 25 μM glutamic acid, 2% (v/v) B-27, and 12 μg/mL gentamycin). Cells were strained through a nylon filter (70 μm), and then 200 μl of the supernatant with an average density of 5000 cells per well was plated in 9.4 × 10.7 × 6.8 (mm) 8-well glass-bottom plates (ibidi GmbH, Martinsried, Germany) previously coated with Poly-D-lysine (PDL) for at least 2 h and washed 3 times with sterile water. Until the day of the experiments, the plated cells were maintained in a humid atmosphere (5% CO₂) at 37 °C with 150 μl of Neurobasal growth medium being added on the seventh day of culture (DIC).

Ca²⁺ imaging

Ca²⁺ signaling recordings from cultured neurons were done as before [48]. Ibidi plates were mounted on an inverted microscope (Axiovert 135TV, Zeiss) with a xenon lamp and 340-nm and 380-nm wavelength bandpass filters. Throughout the experiment, the cells were kept at 37 °C in a humid atmosphere. During the first 5 min of the trial, baseline Ca²⁺ levels were established. Test drugs were then applied directly to the medium with a pipette. At the end of the experiment, the Ca²⁺ ionophore, ionomycin (2 μM), was added and only the cells

that clearly responded to ionomycin with a clear increase in the 340/380 nm ratio were considered for statistical analysis. Zero minutes in the time-course figures represent the time when recordings began.

Image pairs were taken every 10 s with excitation wavelengths of 340 and 380 nm and then used to obtain respective ratio images. The excitation wavelengths were changed using a high-speed wavelength switch, Lambda DG-4 (Sutter Instrument, Novato, CA, USA), and the emission wavelength was set to 510 nm. Image data were recorded by a CCD camera (Photometrics CoolSNAP fx) and processed and analyzed by MetaFluor software (Universal Imaging, West Chester, PA, USA). The regions of interest were obtained by profiling the cells and averaging fluorescence intensity within the delimited area. Intensity values were converted to the 340/380 nm ratio and all values in each cell were normalized to the first recorded ratio.

Ca²⁺ imaging analysis

The frequency of Ca²⁺ transients was determined with MATLAB and Statistics Toolbox Release 2016a, The MathWorks, Inc. (Natick, MA, USA), with a specific roadmap. In the first 5 min of the experiment, a baseline was obtained. Mean and standard error of the mean (S.E.M) of all data recorded by each cell was obtained. Transient validation was performed as described by [49] with some modifications. Cells that had spontaneous Ca²⁺ transients during the first 5 min of the experiment were discarded from the statistical analysis. For a Ca²⁺ transient to be considered valid, the following criteria had to be met: only if the fura-2 excitation wavelength 340-nm and 380-nm (F340/380) ratio transient was greater than the mean of baseline values plus 15 times the S.E.M. of the baseline values that Ca²⁺ transient would be considered. In addition, the normalized ratio must be above this margin for more than 10 s and less than 700 s. For each region of interest, the peak of each transient, as well as the occurrence of transients, was recorded.

Statistical analysis

The statistical analysis was obtained utilizing the software GraphPad Prism 6.01 (GraphPad Software, Inc.). The paired data with two data groups were analyzed using either Student's *t* test or Wilcoxon matched-pairs signed-rank test. Data with more than two groups analyzed were analyzed by a univariate or multivariate ANOVA followed by the Bonferroni post hoc test. The data are expressed as

mean \pm S.E.M. For all tests, $p < 0.05$ was considered to be statistically significant.

Results

Caffeine enhances NMDAR-mediated synaptic currents, an action mimicked by a selective A₁R antagonist

The effect of caffeine on synaptic currents mediated by NMDAR in CA1 hippocampal pyramidal neurons of adolescent mice is summarized in Fig. 1. At a concentration (200 μ M) that fully blocks adenosine receptors [11, 12], it caused a fast and significant increase ($47 \pm 12\%$, $n = 16$ cells from 16 slices from 8 mice, $p < 0.005$) in the amplitude of NMDAR-mediated currents (Fig. 1a,c). At this concentration, caffeine also affects other signaling mechanisms besides blockade of adenosine receptors, as inhibition of phosphodiesterases and Ca²⁺ release from intracellular stores, among others [11, 12], which could be responsible for an excitatory action upon synaptic transmission. To find out whether the facilitation of NMDAR currents by caffeine could be attributed to antagonism of adenosine receptors, we designed three independent experiments aiming (1) to test the action of caffeine at a concentration (30 μ M) that, though submaximal in what respects adenosine receptor blockade, is known to cause minimal effects on phosphodiesterases or other signaling mechanisms [11, 12]; (2) to compare the action of caffeine with the action of a selective antagonist of the inhibitory A₁R receptor; (3) to test whether the facilitatory action of caffeine could be occluded by previous blockade of adenosine A₁R.

Caffeine (30 μ M) also enhanced the peak amplitude of NMDAR-mediated EPSCs (% increase: $47 \pm 16\%$, $n = 9$ cells from 9 slices from 5 mice, $p < 0.03\%$, Fig. 1a,c), the magnitude of the effect being similar to that obtained with 200 μ M (Fig. 1a,c). The selective A₁R antagonist, DPCPX (50 nM), also increased the amplitude of the NMDAR-mediated EPSCs (% increase: $54 \pm 14\%$, $n = 6$ cells from 6 slices from 4 mice, $p < 0.03\%$ Fig. 1a, c), though with a slightly slower time course than caffeine (Fig. 1a). Importantly, in slices that had been previously incubated with DPCPX for 15 min before testing the effect of caffeine, this xanthine was unable to further facilitate NMDAR-mediated EPSCs (% change of currents caused by caffeine in the presence of DPCPX: $1.8 \pm 8.4\%$, $n = 9$ cells from 9 slices from 5 mice Fig. 1b,c).

Altogether, these results indicate that the main mechanism operated by caffeine to increase NMDAR-mediated synaptic currents at the hippocampus is the blockade of A₁R.





Fig. 1 Caffeine, through A_1R , increased the amplitude of NMDAR receptor-mediated synaptic currents. Representative trace of NMDAR currents recorded from one cell before (basal, black trace) and at 10 min after starting perfusion of 200 μM caffeine (red trace). **a** Time course (left panel) and representative EPSCs (right panels) of the effect of caffeine (30 μM or 200 μM) or of the selective A_1R antagonist, DPCPX (50 nM). The horizontal bar in the left panel represents the time of drug perfusion. Each value represents the averaged amplitude of 8 consecutive responses (2 min). **b** Time course (left panel) and representative EPSCs (right panel) of the effect of caffeine (200 μM) in the presence of DPCPX (50 nM). In these experiments, DPCPX was present throughout the recordings and caffeine was added in its presence, as indicated by the horizontal line in the left panel; the representative EPSCs in the right panel are from one cell in DPCPX before (dark trace) and 15 min after adding caffeine, keeping the presence of DPCPX (green trace). **c** Averaged increase in current amplitude caused by the different

experimental conditions shown in panels **a** and **b**. Basal values have been normalized to 1 in each experiment, and represent the amplitude of the currents recorded for 10 min before addition of the test drug (-386.3 ± 95.49 pA before caffeine 200 μM ; -160.4 ± 18.84 pA before caffeine 30 μM ; -290.6 ± 72.05 pA before DPCPX 50 nM and -396.6 ± 144.8 pA before caffeine in the presence of DPCPX 50 nM). Drug effect was measured by averaging responses recorded for the last 2 min of drug perfusion. Data are mean \pm S.E.M.; n values are indicated in each bar and represent the number of cells tested, from the same number of slices from different animals (see text for details); only one drug condition was tested in each cell and slice. * $p < 0.05$ as compared with basal values; # $p < 0.05$ while comparing the effect of caffeine in the absence or presence of DPCPX; ns: $p > 0.05$ as compared with basal values. One-way ANOVA followed by the Bonferroni post hoc test. Note that DPCPX mimicked and prevented the excitatory effect of caffeine

The facilitatory action of caffeine upon NMDAR-mediated EPSCs cannot be attributed to a pre-synaptic facilitatory action upon glutamate release

Adenosine A_1R are known to inhibit the release of neurotransmitters, including the release of glutamate by hippocampal glutamatergic nerve terminals [44, 50, 51]. Therefore, we first hypothesized that caffeine was enhancing NMDAR-mediated EPSCs through a pre-synaptic facilitatory action that would

lead to increased availability of glutamate to activate NMDARs. To test this hypothesis, we evaluated the influence of caffeine upon paired-pulse facilitation (PPF, measured as the ratio between 2nd and 1st NMDAR-mediated EPSC amplitude, interstimulus interval of 250 ms). PPF results from the transient accumulation of calcium inside the nerve terminal due to the two consecutive stimuli and reflects the synaptic release probability, so that the lower the release probability, the higher the PPF [52, 53]. Therefore, drugs that facilitate



◀ **Fig. 2** Influence of caffeine (200 μ M) (a), of the A₁R agonist, DPCPX (50 nM) (c), and of the A_{2A}R antagonist SCH58261 (50 nM) (d) on paired-pulse facilitation (PPF) of NMDAR-mediated synaptic currents (presented as the ratio between 2nd and 1st NMDA-EPSC amplitude). In **b** are shown results from experiments where no drugs were added but the solutions were changed and time of recording kept the same as for testing drugs. PPF values (left panels) and representative current traces (right panels) before (basal) and after 10 min after changeover of solutions to the conditions indicated below each bar (left panels) or next to the tracings (right panels). Data are represented as mean \pm S.E.M; *n* values are shown in each bar and indicate the number of cells tested from an equal number of slices and animals. **p* < 0.05, ns: *p* > 0.05 as compared with basal values before changeover of solutions (Wilcoxon signed-rank test). Note that the A_{2A}R antagonist, SCH 58261, but not DPCPX, mimicked the increase in PPF caused by caffeine

neurotransmitter release are expected to cause a decrease in PPF. Surprisingly, caffeine increased PPF of NMDAR-mediated EPSCs (Fig. 2a: Basal: 1.34 ± 0.08 , *n* = 11 cells from 11 slices from 6 mice; Caffeine: 1.70 ± 0.19 , *n* = 11 cells from 11 slices from 6 mice *p* < 0.03), precluding the possibility that its facilitatory action on NMDA-mediated EPSCs would result from a facilitation of glutamate release.

Blockade of pre-synaptic A_{2A}R is likely involved in a pre-synaptic inhibitory action of caffeine upon transmission

The next series of experiments were designed to understand the nature of the increase in PPF observed in the presence of caffeine. To control for the possibility of a time-dependent run-down of neurotransmitter release leading to a time-dependent increase in PPF, we performed control recordings in the absence of caffeine, keeping the recording time similar to that in the caffeine protocols. Under these control conditions, PPF was not increased (Fig. 2b: Basal: 1.22 ± 0.06 , *n* = 6 cells from 6 slices from 4 mice; % change: 1.19 ± 0.03 , *n* = 6 cells from 6 slices from 4 mice, *p* > 0.05).

We then compared the action of caffeine upon PPF with that of selective A₁R or A_{2A}R antagonists. The enhancement in PPF caused by caffeine could not be attributed to adenosine A₁R blockade because it was not mimicked by DPCPX (Fig. 2c: Basal: 1.31 ± 0.10 , *n* = 7 cells from 7 slices from 5 mice; DPCPX: 1.20 ± 0.04 , *n* = 7 cells from 7 slices from 5 mice). It was, however, mimicked by SCH 58261 at a concentration (50 nM), selective antagonist for adenosine A_{2A}R [54–56] (Fig. 2d, Basal: 1.42 ± 0.08 , *n* = 6 cells from 6 slices from 4 mice; SCH 58261: 1.90 ± 0.30 , *n* = 6 cells from 6 slices from 4 mice, *p* < 0.03).











Altogether, this data suggests that caffeine modulates NMDAR-mediated synaptic currents in two ways: by blocking A₁R, it likely causes a post-synaptic enhancement

of transmission, and by blocking A_{2A}R, it likely decreases availability of glutamate to activate NMDARs.

Caffeine enhances neuronal intracellular Ca²⁺ through A₁R blockade

Considering the relevance of intracellular Ca²⁺ levels for both neurotransmitter release and for the NMDAR-mediated signaling cascade, and considering that caffeine can affect intracellular Ca²⁺ levels, either through adenosine receptor-dependent and adenosine receptor-independent ways [2, 12, 13], we tested the influence of caffeine on intracellular neuronal Ca²⁺ levels and assessed the role of A₁R and A_{2A}R selective antagonists in that action. We evaluated Ca²⁺ signaling by the fluorescence intensity response of Fura2 after consecutive stimulation at 340 nm and 380 nm, and quantified in individual cells the ratio between the two responses (F340/380, Fig. 3c). In a first set of experiments, we tested each drug individually as well as the time-dependent change in the signaling (protocol as in Fig. 3a). Recordings for 35 min after mimicking a drug change (aCSF for aCSF) did not lead to appreciable modifications in the F340/380 ratio (Fig. 3d–e). Caffeine (200 μ M) caused an increase (*p* < 0.03) in the basal F340/380 ratio (Fig. 3d–g) as well as increased the frequency of transient Ca²⁺ signaling events (Fig. 3f, j; Frequency_{Basal}: 0.25 ± 0.06 Ca²⁺ Events/5 min, *n* = 42 4; Frequency_{Caffeine}: 0.78 ± 0.10 Ca²⁺ Events/5 min, *n* = 180 11 *p* < 0.04). DPCPX (50 nM) mimicked the effect of caffeine upon basal Ca²⁺ levels (Fig. 3d, h) as well as upon the frequency of spontaneous events (Fig. 3 h, j; Frequency_{DPCPX}: 0.89 ± 0.19 Ca²⁺ Events/5 min, *n* = 57 3, *p* < 0.04 vs basal). In contrast, SCH 58261 (50 nM) did not appreciably affect either basal Ca²⁺ levels (Fig. 3d, k) and even decreased by near one-half the frequency of spontaneous events (Fig. 3m, Frequency_{SCH58261}: 0.11 ± 0.04 Ca²⁺ Events/5 min, *n* = 54 3 vs Frequency_{Basal}: 0.25 ± 0.06 Ca²⁺ Events/5 min, *n* = 42 4), though this effect did not prove statistically significant.

Next, we evaluated whether a pre-incubation with each of the selective adenosine receptor antagonists could blunt the action of caffeine. Upon addition of DPCPX (50 nM), an initial rise in the F340/380 ratio was detected (Fig. 3i) in agreement with the data obtained in the previous experiments (Fig. 3h). After 15 min in DPCPX, we added caffeine (200 μ M), keeping the presence of DPCPX. Under such conditions, the F340/380 ratio started to decrease back to initial levels (Fig. 3i), suggesting that caffeine has an inhibitory action upon intracellular Ca²⁺ levels, which can be detected when A₁R is blocked. The frequency of signal transients was also decreased by caffeine (200 μ M) in the presence of DPCPX (*p* < 0.04 when comparing DPCPX alone with DPCPX with caffeine), towards values (Frequency_{DPCPX + Caffeine}: 0.16 ± 0.04 Ca²⁺ Events/5 min, *n* = 28 3) even slightly lower than those detected before addition of any drug (Fig. 3j).



◀ **Fig. 3** Caffeine exposure increases intracellular Ca^{2+} levels and the frequency of Ca^{2+} transients in neuron cell culture. **a, b** Time lines representing the order and timing for each drug administration. **c** Ca^{2+} imaging and representative images of relative fluorescence in 340 and 380 nm. **d** Representative images of neurons kept all time in saline (first row) or to be challenged (immediately after min 5) with caffeine (200 μM), DPCPX (50 nM), and SCH 5861 (50 nM), as indicated in the left panel of each row; the recording times are indicated in the top panel of each column; the last column shows the response to the Ca^{2+} ionophore ionomycin (2 μM), to access maximum Ca^{2+} increase, thus an indirect way of accessing cell viability before ionomycin; min 5 (first column) shows responses immediately before addition of drugs. The time course panels show representative tracings (one tracing per cell) of the changes of the ratio between responses to F340 and F380 nanometer wavelength (F340/F380) during exposure to saline (**e**), caffeine (**f**), DPCPX (**h**), caffeine in the presence of DPCPX (**i**), SCH 58261 (**k**), caffeine in the presence of SCH 58261 (**l**), as indicated by the horizontal bars; in each cell, the tracings have been normalized, so that the first ratio of the first recording was taken as 1. Panel **g** illustrates the averaged F340/F380 ratio recorded at 0–5 min in the absence of caffeine and at 40–45 min in the presence of caffeine, as indicated below the bars. Panels **j** and **m** show averaged frequency of Ca^{2+} transients recorded during exposure to the drug conditions indicated below each bar. Values in similar drug conditions in **j** and **m** are from the same cells and are repeated to allow comparisons. Data in **g**, **j**, and **m** are represented as mean \pm S.E.M.; n values are indicated below each bar and correspond to the number of cells/taken from the identified number of independent cultures. * $p < 0.05$; ns: $p > 0.05$ as compared with control values in saline; # $p < 0.05$ as compared with values with caffeine in the absence of the selective adenosine receptor antagonists (Mann-Whitney test in **g**; two-way ANOVA followed by Bonferroni post hoc test in **j** and **m**). Scale bar in **c**: 20 μm and **d**: 10 μm , and applies to all images in the same panel

Considering that inhibitory action of caffeine in the presence of DPCPX had similarities with the effect of the selective $\text{A}_{2\text{A}}$ R antagonist, SCH 58261 (50 nM), when applied alone, we hypothesized that it could result from blockade of $\text{A}_{2\text{A}}$ R. If so, the effect should be blunted by the presence of SCH 58261. It was indeed the case, as can be concluded from the data in Fig. 3m. When caffeine (200 μM) was applied in the presence of SCH 58261, it not only did not inhibit the frequency of Ca^{2+} signals, but even tended to increase the frequency towards a value (Frequency_{SCH58261 + Caffeine}: $0.45 \pm 0.22 \text{ Ca}^{2+} \text{ Events/5 min}$, $n = 28$) intermediate from that observed with caffeine alone and in absence of any drugs (Fig. 3l, m).

We then tested the effect of a lower concentration of caffeine (30 μM) to mitigate its adenosine receptor-independent action upon mobilization of intracellular Ca^{2+} stores. We confirmed that even at this lower and submaximal concentration, caffeine could promote an increase in the frequency of Ca^{2+} transients (Fig. 4a–c: Frequency_{Basal}: $0.29 \pm 0.07 \text{ Ca}^{2+} \text{ Events/5 min}$, $n = 43$ 4; Frequency_{Caffeine 30 μM} : $0.61 \pm 0.08 \text{ Ca}^{2+} \text{ Events/5 min}$, $n = 48$ 2, $p < 0.009$), though being virtually devoid of effect in basal Ca^{2+} levels.

Altogether, these results suggest that caffeine can act at least in two opposite ways to control intracellular Ca^{2+} levels in neurons: (1) through blockade of A_1R leading to increases in basal Ca^{2+} levels as well as to increases in Ca^{2+} transients;

(2) through blockade of $\text{A}_{2\text{A}}$ R leading to decreases in intracellular Ca^{2+} , an action only evident when A_1R is blocked, indicating that the predominant action of caffeine is a result of A_1R blockade.

NMDAR is involved in the facilitatory action of caffeine upon intracellular Ca^{2+} levels

It is well known that NMDAR is permeable to Ca^{2+} [57]. We therefore assessed whether the A_1R -mediated facilitatory action of caffeine upon NMDAR could be related to the facilitatory action of this xanthine upon intracellular Ca^{2+} levels. To test this possibility, we evaluated the effect of caffeine upon Ca^{2+} signaling in neurons in presence of a NMDAR blocker, DL-2-amino-5-phosphonopentanoic acid (AP5). When applied alone, AP5 (50 μM) was virtually devoid of effect upon basal F340/380 ratio (Fig. 5b) as well as upon the frequency of the signal transients (Fig. 5d, Frequency_{Basal}: $0.29 \pm 0.07 \text{ Ca}^{2+} \text{ Events/5 min}$, $n = 43$ 4; Frequency_{AP5}: $0.18 \pm 0.04 \text{ Ca}^{2+} \text{ Events/5 min}$, $n = 79$ 4). Importantly, caffeine applied in the presence of AP5 could no longer increase either the basal Ca^{2+} levels (Fig. 5a–d) or the frequency of the transients (Fig. 5d, Frequency_{AP5 + Caffeine}: $0.23 \pm 0.06 \text{ Ca}^{2+} \text{ Events/5 min}$, $n = 40$ 4). As expected, the effect of caffeine alone was significantly different ($p < 0.007$) from that of caffeine in the presence of AP5 (Fig. 5d). Altogether, these data show that Ca^{2+} entry through NMDAR contributes to the facilitatory action of caffeine upon intracellular neuronal Ca^{2+} signaling.

Discussion

We herein describe for the first time that acute caffeine in micromolar concentrations facilitates NMDAR-mediated synaptic currents and Ca^{2+} signaling on hippocampal neurons and that this effect results from A_1R blockade. The facilitation of synaptic currents could not be attributed to an increase in the pre-synaptic release of glutamate. Conversely, caffeine seems to cause a decrease in glutamate release, an action mimicked by an $\text{A}_{2\text{A}}$ R antagonist suggesting that it may result from $\text{A}_{2\text{A}}$ R blockade. The net effect of caffeine on synaptic NMDAR-mediated currents is, however, a facilitatory one, indicating that under the conditions used, the A_1R -mediated actions prevail over the $\text{A}_{2\text{A}}$ R-mediated ones, which is not surprising on the light of the relative distribution of the two high-affinity receptors at the hippocampus [17, 18]. Concerning the effect of caffeine on Ca^{2+} transients in neurons, we also observed a facilitation mediated by A_1R blockade. The caffeine-induced enhancement of Ca^{2+} transients clearly involved activation of NMDAR, since it was fully prevented in the presence of a NMDAR antagonist. This highlights an inhibitory action of A_1R upon Ca^{2+} entry




Fig. 4 At a lower concentration (30 μ M), caffeine also increases the frequency of Ca^{2+} transients in neurons. **a** Representative images of neurons taken immediately before adding caffeine (left image); caffeine was added at 5 min; the images displayed were taken at the times indicated above each recording; the last image shows the response to the Ca^{2+} ionophore ionomycin (2 μ M), to access maximum Ca^{2+} increase, thus an indirect way of accessing cell viability before ionomycin. **b** Representative tracing of time-course changes of the ratio between responses to F340 and F380 nanometer wavelength during

exposure of one of the cells to caffeine; the tracing has been normalized so that the first ratio of the first recording was taken as 1. Panel c shows averaged frequency of Ca^{2+} transients recorded during caffeine perfusion; data are represented as mean \pm S.E.M; *n* values are indicated below each bar and correspond to the number of cells/taken from the identified number of independent cultures. $**p < 0.01$ as compared with control values in saline (Wilcoxon signed-rank test in c). Note caffeine 30 μ M, mimicked effect of caffeine 200 μ M on the frequency of Ca^{2+} transients. Scale bar in a: 10 μ m, and applies to all images

through NMDAR in hippocampal neurons. Interestingly, when the A_1R was blocked, caffeine slightly decreased Ca^{2+} signals, an effect mimicked by an A_{2A}R antagonist. Again, the facilitation by caffeine prevails upon the inhibitory action when both high-affinity adenosine receptors were available to be blocked.

On the light of the known actions of adenosine receptors upon hippocampal synaptic transmission, the relative distribution of A_1R and A_{2A}R in hippocampal neurons, their predominance in pre-synaptic vs post-synaptic sites at hippocampal synapses [23, 58], as well on the similar affinity of caffeine for A_1R and A_{2A}R [12, 59], one would expect that most of the actions of caffeine upon glutamatergic transmission would be to cancel the pre-synaptic inhibitory action of A_1R upon glutamate release. This has been the canonic interpretation for the facilitatory actions of caffeine upon hippocampal synaptic transmission [28, 56, 60],

long-term potentiation [28], and induction of a non-NMDA form of synaptic plasticity [61].

Due to the relevance of NMDARs not only for synaptic plasticity, cognition, memory, learning [31, 32], synapse formation, remodeling, elimination [62], neuronal migration [63], proliferation, and differentiation [64], but also for excitotoxicity [65], we focused on the possibility that caffeine could modulate the NMDAR-mediated component of glutamatergic transmission. Our data showing that caffeine enhances the NMDAR-mediated component of synaptic currents, through a mechanism that could not be related to pre-synaptic facilitation of neurotransmitter release, suggests that endogenous adenosine is tonically inhibiting NMDARs. Since this action was mimicked by DPCPX and occluded by prior application of DPCPX, the adenosine receptor involved in this tonic modulation might belong to the A_1R subtype. This conclusion agrees with


previous reports that post-synaptic very high-affinity adenosine A₁Rs inhibit NMDA currents in dissociated hippocampal neurons [33] and highlights a role for endogenous adenosine as modulator of NMDAR function. Importantly also, we could show that it impacts in NMDAR-mediated Ca²⁺ oscillations in neurons. Glutamatergic synaptic maturation is highly dependent of synaptic NMDAR activation and Ca²⁺ oscillations at critical time points during development [66]. Thus, proper adjustment of endogenous modulation of NMDARs might be required for appropriate synaptic maturation. Caffeine exposure during gestation has been shown to affect maturation of GABAergic neurons, an action likely mediated by both A₁R [67] and A_{2A}R [68]. The present study showing that caffeine modulates synaptic responses and Ca²⁺ oscillations mediated by NMDARs points towards the possibility that exposure to caffeine during critical developmental periods may also affect fine tuning of glutamatergic circuits, a possibility clearly deserving future research.

The adenosine A₁R-mediated protection against excitotoxicity has been mostly associated to its ability to inhibit glutamate release, whereas A_{2A}R activation leads to excitotoxicity exacerbation [20, 44, 45] and so, neuroprotective actions of caffeine are usually a consequence of A_{2A}R blockade. Since there is plenty of evidence on the neuroprotective actions of caffeine to delay neurodegenerative disease progression, caffeine is frequently referred as having predominant A_{2A}R antagonistic properties. This might be so in brain areas, as the basal ganglia, where A_{2A}R predominate, or in situations where A_{2A}R activity gains particular relevance, as in neurodegeneration or aging, where there is an upregulation of A_{2A}R [69]. But we now used young animals and as we show, at this age, A₁R antagonism by caffeine prevails over A_{2A}R antagonism to influence NMDAR at the hippocampus.

Evidence that tonic activation by A₁R can protect neurons by decreasing NMDAR overactivation under hypoxic conditions has already been published and has been interpreted as a consequence of inhibition of neurotransmitter release [41]. The present work adds a further piece to the puzzling role of neuroprotection by adenosine by showing for the first time results compatible with the conclusion that tonic A₁R activation by endogenous adenosine inhibits NMDAR-mediated responses in hippocampal neurons. As we also show, this inhibition impacts on Ca²⁺ homeostasis, therefore, has a putative protective influence upon excitotoxicity, independently of the A₁R-mediated ability to inhibit glutamate release.

Somehow surprising was the influence of the selective A_{2A}R antagonist upon paired pulse facilitation of NMDAR-mediated EPSCs, an action mimicked by caffeine and compatible with a tonic facilitatory action of A_{2A}R upon glutamate release. The selective A₁R

antagonist was devoid of effect upon PPF. This could result from the absence of pre-synaptic A₁R activation on glutamatergic nerve terminals, which is highly unlikely, considering the well-known influence of A₁R to pre-synaptically inhibit glutamate release at the hippocampus [50, 51, 70]. Indeed, while mostly assessing AMPA receptor-mediated synaptic transmission through field excitatory synaptic potential recordings, it has been observed that DPCPX [71, 72], as well as caffeine due to pre-synaptic A₁R blockade [30], inhibit PPF. Alternatively, our data may indicate that the levels of endogenous adenosine in our experimental conditions are not enough to activate pre-synaptic inhibitory A₁R, though being enough to activate the A₁R inhibitory post-synaptic receptors that reduce NMDAR function. This possibility agrees with reports that effective concentrations of adenosine are at least one order of magnitude lower to inhibit NMDAR-mediated currents [33] than to inhibit synaptic fast excitatory synaptic transmission at the hippocampus [50, 51]. If so, one has to assume either that (1) pre-synaptic inhibitory A₁R receptors have lower affinity for adenosine and/or lower efficacy to control release than pre-synaptic A_{2A}R, or that (2) a facilitation of glutamate release due to pre-synaptic A₁R blockade does not affect NMDAR-mediated responses, whereas an inhibition of glutamate release due to blockade of A_{2A}R-mediated facilitation does. Though we cannot preclude the first possibility (affinity/efficacy differences), the second one seems likely. Thus, to activate synaptic NMDAR, there is a need of strong pre-synaptic stimulation and therefore the consequences of a further facilitation of glutamate release may be more difficult to detect than the consequences of inhibition of glutamate release. NMDAR activation may lead to further activation of NMDAR-mediated responses [73] and this could hamper the increase in EPSC caused by the second stimulus when the release is facilitated by A₁R blockade. This ceiling effect is likely mitigated when release probability is lowered due to blockade of A_{2A}R-mediated facilitation. We can also argue that paired-pulse facilitation of NMDAR-mediated currents encompasses a post-synaptic component besides a pre-synaptic one [74], and therefore the alterations of PPF caused by the A_{2A}R antagonist and caffeine should not be interpreted only on the basis of a decrease of neurotransmitter release due to blockade of pre-synaptic A_{2A}Rs. Indeed, A_{2A}R activation can post-synaptically facilitate NMDAR-mediated currents at the hippocampus [24] and can trigger a NMDAR-dependent form of LTP in hippocampal areas where plasticity is mostly non-NMDAR dependent [35]. A_{2A}R are also known to facilitate synaptic plasticity phenomena both *ex vivo* [30] and *in vivo* [75]. How these A_{2A}R-mediated actions would affect a putative post-synaptic component of the NMDA PPF is difficult to predict.



A biphasic effect of caffeine to control the release of acetylcholine has been reported [76] and tentatively interpreted as resulting from antagonism of A₁ and A₂


receptors known to control acetylcholine release in the cortex [77]. However, different concentrations of caffeine were required to observe the facilitatory and the inhibitory

Fig. 5 The increase in intracellular Ca^{2+} levels and induction of Ca^{2+} transients caused by caffeine (200 μM) is mediated by NMDAR. **a** Representative images of neurons taken at the times indicated on the top of the images; the first row shows images taken from neurons where only the effect of the NMDAR antagonist, AP5 (50 μM), was tested; the second row shows images from neurons where the effect of caffeine in the presence of AP5 was tested; the first image in each row was taken immediately before adding any drug (5 min) and the last image in each row represents the response to the Ca^{2+} ionophore, ionomycin (2 μM), added to access maximum Ca^{2+} increase, thus an indirect way of accessing cell viability before ionomycin; in both rows, the neurons were exposed from 5 min onwards to AP5 (50 μM); in the lower row, the neurons were then further exposed to caffeine (200 μM), which was added at 20 min, therefore between the 2nd and 3rd image. Panels **b** and **c** show representative tracings (one tracing per cell) of the time-course changes of the ratio between responses to F340 and F380 nanometer wavelength during exposure to AP5 only (**b**), or caffeine in the presence of AP5 (**c**), which were added at the times indicated by the horizontal bars; in each cell, the tracings have been normalized so that the first ratio of the first recording was taken as 1. Panel **d** shows averaged frequency of Ca^{2+} transients recorded in the drug conditions indicated below each bar; values under similar drug conditions than those in Fig. 4 j and m are the same and are repeated here to allow comparisons; data are represented as mean \pm S.E.M; n values are indicated below each bar and correspond to number of cells/taken from the identified number of independent cultures. * $p < 0.05$; ns: $p > 0.05$ as compared with control values in saline; # $p < 0.01$ as compared with values with caffeine in the absence of the selective NMDAR antagonists (Two-way ANOVA followed by the Bonferroni post hoc test in **d**). Scale bar in **a**: 10 μm , and applies to all images

effect. We herein show that caffeine can exert this dual role at the same concentration, allowing the suggestion that the relative influence of caffeine likely depends on the relative contribution of the high-affinity adenosine receptors (A_1R and $\text{A}_{2\text{A}}\text{R}$) to control a specific brain function. Importantly, we report a dual role of caffeine as modulator of the activity of a receptor, the NMDA receptor, that by itself has dual functions in the brain.

In conclusion, our data suggest that acute caffeine exposure of hippocampal neurons of adolescent mice has dual and opposing effects on the NMDA component of glutamatergic synaptic transmission. The predominant action is exerted at the post-synaptic level to enhance NMDAR activity via blockade of inhibitory A_1R , with a consequent increase of Ca^{2+} levels. By blocking facilitatory $\text{A}_{2\text{A}}\text{R}$ likely located pre-synaptically, caffeine leads to a decrease in glutamate release probability, a mechanism that may at least in part counteract the excitatory action upon NMDAR-mediated transmission (Fig. 7). These results, showing that relatively low concentrations of caffeine acting upon adenosine receptors can influence NMDAR activity and perturb Ca^{2+} oscillations at the hippocampus, highlight the need to further investigate how early exposure to caffeine during gestational periods or during adolescence affects neuronal differentiation and synaptic maturation, known to be highly dependent of properly adjusted Ca^{2+} homeostasis.

Fig. 6 Schematization of caffeine action on its adenosine receptors targets and their impact in NMDAR-mediated responses. At the post-synaptic level caffeine acts via A_1R blockade, affecting Ca^{2+} homeostasis by promoting an increase in Ca^{2+} entry through NMDAR. At the pre-synaptic level, caffeine, by blocking $\text{A}_{2\text{A}}\text{R}$, decreases glutamate release, which may counteract the excitatory action and, in such way, contribute to maintaining synaptic transmission homeostasis. Changes in the relative contribution to these two opposing actions throughout life as well as under different pathologies may lead to different global actions of caffeine on NMDAR-mediated responses



Acknowledgments The authors in Portugal are members of an EU twinning action (Project grant 952455). While revising this work, the authors want to make a special tribute to Geoffrey Burnstock for his great contributions to science, for defending and enlarging the knowledge of the purinergic field to the very end of his life, for his friendship and trust even in very difficult circumstances, which will never be forgotten. Thanks Geoff. Your legacy will last forever. We will miss your loud voice and laugh.

Code availability Not applicable

Funding Robertta Silva Martins was in receipt of a fellowship from Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro–FAPERJ, Brasil, Bolsa de Doutorado Sanduíche Europa/Oriente (grant number E-26/201.599/2018). The work was supported by Fundação para a Ciência e Tecnologia, Portugal (project grant PTDC/MED-FAR/30933/2017).

Data availability Not applicable

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflict of interest.

Ethics approval All experimental procedures were performed according to European Community Guidelines (Directive 2010/63/EU) and the Portuguese Law (DL 113/2013) for animal care for research purposes and were approved by the “Instituto de Medicina Molecular” Internal Committee and the Portuguese Animal Ethics Committee - Direcção Geral de Veterinária.

Consent to participate Not applicable

Consent for publication Not applicable

References

- Meeusen R, Roelands B, Spriet LL (2013) Caffeine, exercise and the brain. *Nestle Nutr Inst work Ser* 76:1–12. <https://doi.org/10.1159/000350223>
- Cappelletti S, Piacentino D, Sani G, Aromatario M (2015) Caffeine: cognitive and physical performance enhancer or psychoactive drug? *Curr Neuropharmacol* 13:71–88. <https://doi.org/10.2174/1570159X13666141210215655>
- Hackett PH (2010) Caffeine at high altitude: java at base cAMP. *High alt med biol* 11:13–17. <https://doi.org/10.1089/ham.2009.1077>
- Mitchell DC, Hockenberry J, Teplansky R, Hartman TJ (2015) Assessing dietary exposure to caffeine from beverages in the U.S. population using brand-specific versus category-specific caffeine values. *Food Chem Toxicol* 80:247–252. <https://doi.org/10.1016/j.fct.2015.03.024>
- Poole RL, Braak D, Gould TJ (2016) Concentration- and age-dependent effects of chronic caffeine on contextual fear conditioning in C57BL/6J mice. *Behav brain res* 298:69–77. <https://doi.org/10.1016/j.bbr.2015.03.045>
- Wikoff D, Welsh BT, Henderson R et al (2017) Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. *Food Chem Toxicol* 109:585–648. <https://doi.org/10.1016/j.fct.2017.04.002>
- Ludden AB, O'Brien EM, Pasch KE (2017) Beliefs, behaviors, and contexts of adolescent caffeine use: a focus group study. *Subst use misuse* 52:1207–1218. <https://doi.org/10.1080/10826084.2017.1302957>
- Nehlig A (2016) Effects of coffee/caffeine on brain health and disease: what should I tell my patients? *Pr Neurol* 16:89–95. <https://doi.org/10.1136/practneurol-2015-001162>
- Verster JC (2014) Caffeine consumption in children, adolescents and adults. *Curr Drug Abuse Rev* 7:133–134
- Williams M, Jarvis MF (1988) Adenosine antagonists as potential therapeutic agents. *Pharmacol Biochem Behav* 29:433–441
- Daly JW, Fredholm BB (1998) Caffeine—an atypical drug of dependence. *Drug alcohol depend* 51:199–206. [https://doi.org/10.1016/S0376-8716\(98\)00077-5](https://doi.org/10.1016/S0376-8716(98)00077-5)
- Fredholm BB, Battig K, Holmen J et al (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev* 51:83–133
- Ribeiro JA, Sebastiao AM (2010) Caffeine and adenosine. *J Alzheimers Dis* 20(Suppl 1):S3–S15. <https://doi.org/10.3233/JAD-2010-1379>
- Fredholm BB, Yang J, Wang Y (2017) Low, but not high, dose caffeine is a readily available probe for adenosine actions. *Mol asp med* 55:20–25. <https://doi.org/10.1016/j.mam.2016.11.011>
- Dunwiddie TV, Hoffer BJ, Fredholm BB (1981) Alkylxanthines elevate hippocampal excitability - evidence for a role of endogenous adenosine. *Naunyn Schmiedebergs arch Pharmacol* 316:326–330. <https://doi.org/10.1007/BF00501365>
- Sheth S, Brito R, Mukherjee D et al (2014) Adenosine receptors: expression, function and regulation. *Int J Mol Sci* 15:2024–2052. <https://doi.org/10.3390/ijms15022024>
- Sebastião AM, Ribeiro JA (2009) Adenosine receptors and the central nervous system. *Handb Exp Pharmacol* 193:471–534
- Ribeiro JA, Sebastiao AM, de Mendonca A (2002) Adenosine receptors in the nervous system: pathophysiological implications. *Prog Neurobiol* 68:377–392
- Fredholm BB, IJ AP, Jacobson KA et al (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev* 53:527–552
- Sebastião AM, Ribeiro JA (1996) Adenosine A2 receptor-mediated excitatory actions on the nervous system. *Prog Neurobiol* 48:167–189. [https://doi.org/10.1016/0301-0082\(95\)00035-6](https://doi.org/10.1016/0301-0082(95)00035-6)
- Li XX, Nomura T, Aihara H, Nishizaki T (2001) Adenosine enhances glial glutamate efflux via A2a adenosine receptors. *Life Sci* 68:1343–1350
- Rodrigues RJ, Alfaro TM, Rebola N et al (2005) Co-localization and functional interaction between adenosine a(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. *J Neurochem* 92:433–441. <https://doi.org/10.1111/j.1471-4159.2004.02887.x>
- Rebola N, Canas PM, Oliveira CR, Cunha RA (2005) Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. *Neuroscience* 132:893–903. <https://doi.org/10.1016/j.neuroscience.2005.01.014>
- Mouro FM, Rombo DM, Dias RB, et al (2018) Adenosine A2A receptors facilitate synaptic NMDA currents in CA1 pyramidal neurons. *Br J Pharmacol* 175:4386–4397. <https://doi.org/10.1111/bph.14497>
- Arendash GW, Cao C (2010) Caffeine and coffee as therapeutics against Alzheimer's disease. *J Alzheimers dis* 20 Suppl 1:S117-26. <https://doi.org/10.3233/JAD-2010-091249>
- de Mendonca A, Cunha RA (2010) Therapeutic opportunities for caffeine in Alzheimer's disease and other neurodegenerative disorders. *J Alzheimers dis* 20 Suppl 1:S1-2. <https://doi.org/10.3233/JAD-2010-01420>
- Alhaider IA, Aleisa AM, Tran TT, Alzoubi KH, Alkadhi KA (2010) Chronic caffeine treatment prevents sleep deprivation-

- induced impairment of cognitive function and synaptic plasticity. *Sleep* 33:437–444
28. Costenla AR, Cunha RA, de Mendonca A (2010) Caffeine, adenosine receptors, and synaptic plasticity. *J Alzheimers dis* 20(Suppl 1):S25–S34. <https://doi.org/10.3233/JAD-2010-091384>
 29. Faivre E, Coelho JE, Zornbach K, et al (2018) Beneficial effect of a selective adenosine A2A receptor antagonist in the APPsw/PS1dE9 mouse model of Alzheimer's disease. *Front Mol Neurosci* 11:235. <https://doi.org/10.3389/fnmol.2018.00235>
 30. Lopes JP, Pliassova A, Cunha RA (2019) The physiological effects of caffeine on synaptic transmission and plasticity in the mouse hippocampus selectively depend on adenosine A1 and A2A receptors. *Biochem Pharmacol* 166:313–321. <https://doi.org/10.1016/j.bcp.2019.06.008>
 31. Dore K, Stein IS, Brock JA et al (2017) Unconventional NMDA receptor signaling. *J Neurosci* 37:10800–10807. <https://doi.org/10.1523/JNEUROSCI.1825-17.2017>
 32. Vyklicky V, Korinek M, Smejkalova T et al (2014) Structure, function, and pharmacology of NMDA receptor channels. *Physiol Res* 63(Suppl 1):S191–S203
 33. de Mendonca A, Sebastiao AM, Ribeiro JA (1995) Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. *Neuroreport* 6:1097–1100
 34. Deng Q, Terunuma M, Fellin T, et al (2011) Astrocytic activation of A1 receptors regulates the surface expression of NMDA receptors through a Src kinase dependent pathway. *Glia* 59:1084–1093. <https://doi.org/10.1002/glia.21181>
 35. Rebola N, Lujan R, Cunha RA, Mulle C (2008) Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. *Neuron* 57:121–134. <https://doi.org/10.1016/j.neuron.2007.11.023>
 36. Sarantis K, Tsiamaki E, Kouvaros S, et al (2015) Adenosine a(2) a receptors permit mGluR5-evoked tyrosine phosphorylation of NR2B (Tyr1472) in rat hippocampus: a possible key mechanism in NMDA receptor modulation. *J Neurochem* 135:714–726. <https://doi.org/10.1111/jnc.13291>
 37. Kouvaros S, Papatheodoropoulos C (2016) Major dorsoventral differences in the modulation of the local CA1 hippocampal network by NMDA, mGlu5, adenosine A2A and cannabinoid CB1 receptors. *Neuroscience* 317:47–64. <https://doi.org/10.1016/j.neuroscience.2015.12.059>
 38. Tebano MT, Martire A, Rebola N, et al (2005) Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-d-aspartate effects. *J Neurochem* 95:1188–1200. <https://doi.org/10.1111/j.1471-4159.2005.03455.x>
 39. Temido-Ferreira M, Ferreira DG, Batalha VL, et al (2018) Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. *Mol psychiatry* 1–25. <https://doi.org/10.1038/s41380-018-0110-9>
 40. Krania P, Dimou E, Bantouna M, et al (2018) Adenosine a_{2A} receptors are required for glutamate mGluR5- and dopamine D1 receptor-evoked ERK1/2 phosphorylation in rat hippocampus: involvement of NMDA receptor. *J Neurochem* 145:217–231. <https://doi.org/10.1111/jnc.14268>
 41. Sebastiao AM, de Mendonca A, Moreira T, Ribeiro JA (2001) Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. *J Neurosci* 21:8564–8571
 42. Zhang DS, Ren LM, Zhang L (2004) [Relation between adenosine A1 receptor and NMDA receptor on synaptic transmission in dentate gyrus of hippocampus]. *Yao Xue Xue Bao* 39:245–249
 43. Costenla AR, Diogenes MJ, Canas PM et al (2011) Enhanced role of adenosine a(2A) receptors in the modulation of LTP in the rat hippocampus upon ageing. *Eur J Neurosci* 34:12–21. <https://doi.org/10.1111/j.1460-9568.2011.07719.x>
 44. Cunha RA (2016) How does adenosine control neuronal dysfunction and neurodegeneration? *J Neurochem* 139:1019–1055. <https://doi.org/10.1111/jnc.13724>
 45. Ribeiro FF, Xapelli S, Miranda-Lourenco C et al (2016) Purine nucleosides in neuroregeneration and neuroprotection. *Neuropharmacology* 104:226–242. <https://doi.org/10.1016/j.neuropharm.2015.11.006>
 46. Dong ZS, Cao ZP, Shang YJ et al (2019) Neuroprotection of cordycepin in NMDA-induced excitotoxicity by modulating adenosine A1 receptors. *Eur J Pharmacol* 853:325–335. <https://doi.org/10.1016/j.ejphar.2019.04.015>
 47. Jeronimo-Santos A, Vaz SH, Parreira S et al (2015) Dysregulation of TrkB receptors and BDNF function by amyloid-beta peptide is mediated by Calpain. *Cereb cortex* 25:3107–3121. <https://doi.org/10.1093/cercor/bhu105>
 48. Ferreira DG, Temido-Ferreira M, Miranda H V, et al (2017) Alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. *Nat Neurosci* 20:1569–1579. <https://doi.org/10.1038/nn.4648>
 49. Horvat A, Zorec R, Vardjan N (2016) Adrenergic stimulation of single rat astrocytes results in distinct temporal changes in intracellular Ca(2+) and cAMP-dependent PKA responses. *Cell calcium* 59:156–163. <https://doi.org/10.1016/j.ceca.2016.01.002>
 50. Dunwiddie TV, Masino SA (2001) The role and regulation of adenosine in the central nervous system. *Annu rev Neurosci* 24:31–55. <https://doi.org/10.1146/annurev.neuro.24.1.31>
 51. Corradetti R, Lo Conte G, Moroni F et al (1984) Adenosine decreases aspartate and glutamate release from rat hippocampal slices. *Eur J Pharmacol* 104:19–26. [https://doi.org/10.1016/0014-2999\(84\)90364-9](https://doi.org/10.1016/0014-2999(84)90364-9)
 52. Creager R, Dunwiddie T, Lynch G (1980) Paired-pulse and frequency facilitation in the CA1 region of the in vitro rat hippocampus. *J Physiol* 299:409–424. <https://doi.org/10.1113/jphysiol.1980.sp013133>
 53. Zucker RS, Regehr WG (2002) Short-term synaptic plasticity. *Annu rev Physiol* 64:355–405. <https://doi.org/10.1146/annurev.physiol.64.092501.114547>
 54. Ongini E, Dionisotti S, Gessi S et al (1999) Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. *Naunyn Schmiedebergs arch Pharmacol* 359:7–10. <https://doi.org/10.1007/pl00005326>
 55. Ongini E, Monopoli A, Cacciari B, Baraldi PG (2001) Selective adenosine A2A receptor antagonists. *Farmaco* 56:87–90. [https://doi.org/10.1016/s0014-827x\(01\)01024-2](https://doi.org/10.1016/s0014-827x(01)01024-2)
 56. Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S (1996) The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. *J Pharmacol Exp Ther* 276:398–404
 57. Iacobucci GJ, Popescu GK (2017) NMDA receptors: linking physiological output to biophysical operation. *Nat rev Neurosci* 18:236–249. <https://doi.org/10.1038/nrn.2017.24>
 58. Sebastião AM, Ribeiro JA (2015) Neuromodulation and metamodulation by adenosine: impact and subtleties upon synaptic plasticity regulation. *Brain res* 1621:102–113. <https://doi.org/10.1016/j.brainres.2014.11.008>
 59. Daly JW, Fredholm BB (1998) Caffeine—an atypical drug of dependence. *Drug Alcohol Depend* 51:199–206
 60. Simons SB, Caruana DA, Zhao M, Dudek SM (2012) Caffeine-induced synaptic potentiation in hippocampal CA2 neurons. *Nat Neurosci* 15:23–25. <https://doi.org/10.1038/nrn.2962>
 61. Martín ED, Buño W (2003) Caffeine-mediated presynaptic long-term potentiation in hippocampal CA1 pyramidal neurons. *J*

- Neurophysiol 89:3029–3038. <https://doi.org/10.1152/jn.00601.2002>
62. McKinney RA (2010) Excitatory amino acid involvement in dendritic spine formation, maintenance and remodelling. *J Physiol* 588: 107–116. <https://doi.org/10.1113/jphysiol.2009.178905>
 63. Manent JB, Represa A (2007) Neurotransmitters and brain maturation: early paracrine actions of GABA and glutamate modulate neuronal migration. *Neuroscientist* 13:268–279. <https://doi.org/10.1177/1073858406298918>
 64. Schlett K (2006) Glutamate as a modulator of embryonic and adult neurogenesis. *Curr Top Med Chem* 6:949–960
 65. Traynelis SF, Wollmuth LP, McBain CJ et al (2010) Glutamate receptor ion channels: structure, regulation, and function. *Pharmacol rev* 62:405–496. <https://doi.org/10.1124/pr.109.002451>
 66. Allene C, Cossart R (2010) Early NMDA receptor-driven waves of activity in the developing neocortex: physiological or pathological network oscillations? *J Physiol* 588:83–91. <https://doi.org/10.1113/jphysiol.2009.178798>
 67. Pereira-Figueiredo D, Brito R, Araújo DSM, et al (2020) Caffeine exposure ameliorates acute ischemic cell death in avian developing retina. *Purinergic signal* 16:41–59. <https://doi.org/10.1007/s11302-020-09687-1>
 68. Silva CG, Métin C, Fazeli W, et al (2013) Adenosine receptor antagonists including caffeine alter fetal brain development in mice. *Sci Transl med* 5:197ra104–197ra104. <https://doi.org/10.1126/scitranslmed.3006258>
 69. Diógenes MJ, Assaife-Lopes N, Pinto-Duarte A et al (2007) Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. *Hippocampus* 17:577–585. <https://doi.org/10.1002/hipo.20294>
 70. Dumas TC, Foster TC (1998) Late developmental changes in the ability of adenosine A1 receptors to regulate synaptic transmission in the hippocampus. *Brain Res Dev Brain Res* 105:137–139
 71. Coppi E, Pugliese AM, Stephan H et al (2007) Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices. *Purinergic signal* 3:203–219. <https://doi.org/10.1007/s11302-006-9049-4>
 72. Fusco I, Cherchi F, Catarzi D et al (2019) Functional characterization of a novel adenosine A2B receptor agonist on short-term plasticity and synaptic inhibition during oxygen and glucose deprivation in the rat CA1 hippocampus. *Brain res bull* 151:174–180. <https://doi.org/10.1016/j.brainresbull.2019.05.018>
 73. Markram H, Segal M (1992) The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA. *J Physiol* 447:513–533. <https://doi.org/10.1113/jphysiol.1992.sp019015>
 74. Clark KA, Randall AD, Collingridge GL (1994) A comparison of paired-pulse facilitation of AMPA and NMDA receptor-mediated excitatory postsynaptic currents in the hippocampus. *Exp brain res* 101:272–278. <https://doi.org/10.1007/bf00228747>
 75. Fontinha BM, Delgado-García JM, Madroñal N et al (2009) Adenosine a(2A) receptor modulation of hippocampal CA3-CA1 synapse plasticity during associative learning in behaving mice. *Neuropsychopharmacology* 34:1865–1874. <https://doi.org/10.1038/npp.2009.8>
 76. Pedata F, Pepeu G, Spignoli G (1984) Biphasic effect of methylxanthines on acetylcholine release from electrically-stimulated brain slices. *Br J Pharmacol* 83:69–73. <https://doi.org/10.1111/j.1476-5381.1984.tb10120.x>
 77. Spignoli G, Pedata F, Pepeu G (1984) A1 and A2 adenosine receptors modulate acetylcholine release from brain slices. *Eur J Pharmacol* 97:341–342. [https://doi.org/10.1016/0014-2999\(84\)90475-8](https://doi.org/10.1016/0014-2999(84)90475-8)

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.